Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
- |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
- |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
65.80% |
| Date | Value |
|---|
| Mar 31, 2026 |
65.80% |
| Dec 31, 2025 |
241.26% |
| Sep 30, 2025 |
-109.29% |
| Jun 30, 2025 |
124.42% |
| Mar 31, 2025 |
63.52% |
| Dec 31, 2024 |
219.81% |
| Sep 30, 2024 |
-124.85% |
| Jun 30, 2024 |
-881.20% |
| Mar 31, 2024 |
-28.40% |
| Dec 31, 2023 |
-202.85% |
| Sep 30, 2023 |
611.91% |
| Jun 30, 2023 |
-41.03% |
| Mar 31, 2023 |
3.03% |
| Dec 31, 2022 |
114.34% |
| Sep 30, 2022 |
65.69% |
| Jun 30, 2022 |
-70.48% |
| Mar 31, 2022 |
-98.63% |
| Dec 31, 2021 |
-160.27% |
| Sep 30, 2021 |
63.46% |
| Jun 30, 2021 |
-96.44% |
